Health & bio

BeOne TEVIMBRA Wins Priority Review for HER2+ Gastric/Esophageal Cancer

BeOne Medicines' TEVIMBRA granted priority review for first-line HER2+ gastroesophageal adenocarcinoma. Expands immunotherapy first-line options.

Primary sources · 1
FDA
← View the full 2026-04-30 (Thursday) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →